ArticleJCO precision oncology2017

Precision Oncology Strategy in Trastuzumab-Resistant Human Epidermal Growth Factor Receptor 2-Positive Colon Cancer: Case Report of Durable Response to Ado-Trastuzumab Emtansine.

Derrick S Haslem et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.